Wellington Management Group LLP Has $38.48 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Wellington Management Group LLP trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 29.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 533,710 shares of the medical equipment provider's stock after selling 220,542 shares during the period. Wellington Management Group LLP owned approximately 0.24% of Hologic worth $38,475,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC raised its position in Hologic by 2.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock worth $9,399,000 after purchasing an additional 3,655 shares in the last quarter. Blue Trust Inc. boosted its stake in Hologic by 18.4% in the 4th quarter. Blue Trust Inc. now owns 8,428 shares of the medical equipment provider's stock valued at $608,000 after buying an additional 1,310 shares in the last quarter. KBC Group NV raised its stake in Hologic by 6.6% during the fourth quarter. KBC Group NV now owns 93,376 shares of the medical equipment provider's stock worth $6,731,000 after acquiring an additional 5,747 shares in the last quarter. Custom Index Systems LLC raised its stake in Hologic by 7.1% during the fourth quarter. Custom Index Systems LLC now owns 9,379 shares of the medical equipment provider's stock worth $676,000 after acquiring an additional 618 shares in the last quarter. Finally, Mather Group LLC. lifted its holdings in shares of Hologic by 236.0% during the fourth quarter. Mather Group LLC. now owns 2,937 shares of the medical equipment provider's stock valued at $212,000 after acquiring an additional 2,063 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HOLX. Stephens cut their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Finally, Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has an average rating of "Hold" and an average target price of $77.42.

Hologic Trading Down 0.3%

Shares of HOLX traded down $0.16 on Monday, reaching $62.01. 2,584,438 shares of the company's stock were exchanged, compared to its average volume of 2,269,862. The business has a 50 day moving average price of $58.14 and a two-hundred day moving average price of $65.80. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The stock has a market capitalization of $13.82 billion, a P/E ratio of 19.56, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.